External broker reports(aggregated public sources), Motilal Oswal Financial Services Limited

Motilal Oswal

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Motilal Oswal Financial Services Limited

Motilal Oswal Financial Services Limited is an Indian diversified financial services firm offering a range of financial products and services. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<div><ul><li>Promising start for Drolute and Xsulin - T<span style="font-size: var(--content-font-size);">he Dydrogesterone market is at an interesting phase, with an improvement in </span><span style="font-size: var(--content-font-size);">demand due to better access, affordability, and technical superiority over </span><span style="font-size: var(--content-font-size);">Progesterone.</span></li></ul><div><ul><li>Favorable demand-supply and marketing efforts to drive ‘Drolute’ sales for ERIS</li></ul><div><ul><li>Well-positioned to gain market share in the Insulin market - <span style="font-size: var(--content-font-size);">ERIS has expanded its Anti-Diabetic offering, with the recent launch of human/premix Insulin</span></li></ul></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Promising start for Drolute and Xsulin - The Dydrogesterone market is at an interesting phase, with an improvement in demand due to better access, affordability, and technical superiority over Progesterone.Favorable demand-supply and marketing efforts to drive ‘Drolute’ sales for ERISWell-positioned to gain market share in the Insulin market - ERIS has expanded its Anti-Diabetic offering, with the recent launch of human/premix InsulinContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Eris Lifesciences - Niche Launches to Aid Growth over the Medium Term